adplus-dvertising
Connect with us

Business

COMMENTARY: How Canada's COVID-19 vaccine strategy could impact the world – Global News

Published

 on


When the throne speech was delivered on Sept. 23, Canada had already committed over $1 billion in advance purchase agreements with five drug companies for a minimum of 154 million vaccine doses, if and when these candidate vaccines are proven effective and safe.

Two days later, Canada inked another agreement with another company for 20 million more doses, hedging its bets on which of the vaccine contenders will be the first to arrive.

In doing so, Canada joins the premier league of the vaccine nationalists, a handful of rich countries that have pre-purchased (so far) more than half the world’s expected short-term supply of vaccines.

READ MORE: Canada signs deal to obtain 20M doses of Oxford coronavirus vaccine candidate

It is understandable that countries want to ensure their ability to protect their citizens’ health. But most of the world’s population lives in countries without the same financial resources to play the global “me first” vaccine contest. Efforts to elevate national interests over collective global health result in slower progress and limited global capacity to pool resources, while placing the interests of wealthy countries over others, with devastating effects.

Story continues below advertisement

Recent modelling compared two scenarios for allocating the first three billion doses of a vaccine that is 80 per cent effective. The “uncooperative” scenario — in which two billion doses went straight to high-income countries, and the rest to everybody else — would lead to 28 per cent more deaths than a “cooperative” scenario, in which the three billion doses are distributed globally, proportional to population size.






1:40
Canada signs new coronavirus vaccine deals


Canada signs new coronavirus vaccine deals

What can Canada do?

To begin, our pledge to the World Health Organization’s COVAX Facility’s Advanced Market Commitment (AMC) should, at a minimum, match what we invest in procuring vaccine for use within Canada. The facility manages the world’s largest and most diverse portfolio of vaccine candidates. High-income countries like Canada that join COVAX have the option to purchase approved vaccines through the facility, even if they have already entered into bilateral purchase agreements with vaccine companies. On Sept. 25, Canada announced that it would do so, committing $220 million to purchase 15 million more vaccine doses from the facility if and as they are approved.

Story continues below advertisement

Arguably of more importance, the facility’s AMC will provide vaccines to more than 90 eligible poorer countries unable to afford them on their own. The AMC needs to raise $2 billion by December to do so, with the short-term goal of immunizing three per cent of all COVAX countries’ populations. As of Sept. 21, only $700 million had been promised. On Sept. 25, Canada committed $220 million to the AMC, on top of $25 million it had already given. This is welcome and commendable, but it is also inadequate.

The AMC’s longer-term aim is to reach 20 per cent — a goal that will allow health-care workers and vulnerable populations in poor countries to receive vaccines — but this will depend entirely on how generously high-income countries, philanthropists and drug companies donate to the AMC.

[embedded content]
COVAX aims to ensure global equitable access to COVID-19 vaccines.

Much more AMC funding is needed now, and going forward. We argue that Canada should commit a dollar-per-dollar amount to the AMC based on what it spends on its own vaccine purchases. This would mean providing up to $1 billion more than its current AMC pledge, with funds flowing through our country’s official development assistance (ODA) envelope. Canada has global obligations under international declarations to do so.

Story continues below advertisement

Canada says it is a voice for equity and human rights, at home and on the global stage. Actions speak louder than words. Canada in recent years has not been particularly generous in its overseas assistance. We ranked 17th out of 30 of the OECD club of donor nations in 2019, contributing just 0.27 per cent of our gross national income, with no forseeable increase. A $1 billion immediate AMC top-up would still not lift us to our long-pledged 0.7 per cent ODA target.

One billion dollars sounds like a lot of money. But it is only one-fifth the amount the federal government has borrowed weekly since March from the Bank of Canada (which it owns) to finance its pandemic assistance programs. Most less-endowed countries lack the same ability to borrow indefinitely from their own central banks and instead must turn to foreign creditors, with the debt-burden risks that entails. Or do without.

COMMENTARY: (July 12, 2020) ‘Vaccine nationalism’ could threaten Canada’s access to a COVID-19 vaccine

Vaccine manufacturing

According to the CEO of the world’s largest vaccine maker, the Serum Institute of India, even with expanded global capacity, it may take until 2024 before there are enough doses for the world’s population. In addition to ensuring more generous support for the COVAX Facility, Canada can also ramp up its own vaccine manufacturing capacity. It’s already on a pathway to do so, with the government’s $126-million investment for a new facility in Montréal. The facility’s goal is to produce two million vaccine doses per month for domestic use by summer 2021.

Story continues below advertisement

Why not double-down on this investment, and reserving half the output for AMC use to meet urgent global needs? This would signify to all Canadians the importance of a collective response to this pandemic.

Public health is global

As the world eagerly awaits arrival of an effective vaccine, it’s important to remember three things. First, the longer-term effectiveness of any vaccine will remain uncertain for some time. Second, even if herd immunity to COVID-19 eventually develops, there will almost certainly be another novel infection in the not-so-distant future. Third, one way to deal with both future pandemic risks and the present short supply of COVID-19 vaccine is to embrace the range of non-pharmaceutical interventions that can flatten and even contain infectious curves. This is especially so in those countries that are home to the half of humanity who still lack access to essential health care.

Gov. Gen. Julie Payette, wearing a white suit, sits in the ornate chair reserved for the governor general, on a raised platform. The prime minister sits in front of her on the left, with a man wearing a uniform behind him. They all wear black face masks.
Gov. Gen. Julie Payette and Prime Minister Justin Trudeau wait during the throne speech in the Senate chamber in Ottawa on Wednesday, Sept. 23, 2020. The speech noted Canada’s commitment to ensuring global access to a COVID-19 vaccine THE CANADIAN PRESS/Adrian Wyld

All countries need stronger public health workforces: more nurses, testers, contact tracers and community health workers. All countries need universal health coverage, one of the Sustainable Development Goal targets to which the world (Canada included) committed to achieve by 2030. But it is the poorer half of humanity who needs this more urgently.

Story continues below advertisement

So, if Canada and other rich countries in their vaccine nationalism continue inadvertently to crowd out access for poor countries, they should compensate by massively underwriting the investments such countries need to provide the social protection, income support and food security basic to their citizens’ health, and to strengthen their health systems with the public health capacity to suppress outbreaks as they arise.

It is in our own national interest to do so. As the Sept. 23 throne speech concluded:

“We cannot eliminate this pandemic in Canada unless we end it everywhere.”The Conversation

Ronald Labonte, professor and distinguished research chair, globalization and health equity, L’Université d’Ottawa/University of Ottawa; Katrina Plamondon, assistant professor, School of Nursing, Faculty of Health & Social Development, University of British Columbia; Mira Johri, professeure titulaire, École de santé publique, Université de Montréal, and Srinivas Murthy, clinical associate professor, Faculty of Medicine, University of British Columbia

Story continues below advertisement

This article is republished from The Conversation under a Creative Commons licence. Read the original article.

Let’s block ads! (Why?)

728x90x4

Source link

Business

Stop Asking Your Interviewer Cliché Questions

Published

 on

Most job search advice is cookie-cutter. The advice you’re following is almost certainly the same advice other job seekers follow, making you just another candidate following the same script.

In today’s hyper-competitive job market, standing out is critical, a challenge most job seekers struggle with. Instead of relying on generic questions recommended by self-proclaimed career coaches, which often lead to a forgettable interview, ask unique, thought-provoking questions that’ll spark engaging conversations and leave a lasting impression.

English philosopher Francis Bacon once said, “A prudent question is one half of wisdom.”

The questions you ask convey the following:

  • Your level of interest in the company and the role.
  • Contributing to your employer’s success is essential.
  • You desire a cultural fit.

Here are the top four questions experts recommend candidates ask; hence, they’ve become cliché questions you should avoid asking:

  • “What are the key responsibilities of this position?”

Most likely, the job description answers this question. Therefore, asking this question indicates you didn’t read the job description. If you require clarification, ask, “How many outbound calls will I be required to make daily?” “What will be my monthly revenue target?”

  • “What does a typical day look like?”

Although it’s important to understand day-to-day expectations, this question tends to elicit vague responses and rarely leads to a deeper conversation. Don’t focus on what your day will look like; instead, focus on being clear on the results you need to deliver. Nobody I know has ever been fired for not following a “typical day.” However, I know several people who were fired for failing to meet expectations. Before accepting a job offer, ensure you’re capable of meeting the employer’s expectations.

  • “How would you describe the company culture?”

Asking this question screams, “I read somewhere to ask this question.” There are much better ways to research a company’s culture, such as speaking to current and former employees, reading online reviews and news articles. Furthermore, since your interviewer works for the company, they’re presumably comfortable with the culture. Do you expect your interviewer to give you the brutal truth? “Be careful of Craig; get on his bad side, and he’ll make your life miserable.” “Bob is close to retirement. I give him lots of slack, which the rest of the team needs to pick up.”

Truism: No matter how much due diligence you do, only when you start working for the employer will you experience and, therefore, know their culture firsthand.

  • “What opportunities are there for professional development?”

When asked this question, I immediately think the candidate cares more about gaining than contributing, a showstopper. Managing your career is your responsibility, not your employer’s.

Cliché questions don’t impress hiring managers, nor will they differentiate you from your competition. To transform your interaction with your interviewer from a Q&A session into a dynamic discussion, ask unique, insightful questions.

Here are my four go-to questions—I have many moreto accomplish this:

  • “Describe your management style. How will you manage me?”

This question gives your interviewer the opportunity to talk about themselves, which we all love doing. As well, being in sync with my boss is extremely important to me. The management style of who’ll be my boss is a determining factor in whether or not I’ll accept the job.

  • “What is the one thing I should never do that’ll piss you off and possibly damage our working relationship beyond repair?”

This question also allows me to determine whether I and my to-be boss would be in sync. Sometimes I ask, “What are your pet peeves?”

  • “When I join the team, what would be the most important contribution you’d want to see from me in the first six months?”

Setting myself up for failure is the last thing I want. As I mentioned, focus on the results you need to produce and timelines. How realistic are the expectations? It’s never about the question; it’s about what you want to know. It’s important to know whether you’ll be able to meet or even exceed your new boss’s expectations.

  • “If I wanted to sell you on an idea or suggestion, what do you need to know?”

Years ago, a candidate asked me this question. I was impressed he wasn’t looking just to put in time; he was looking for how he could be a contributing employee. Every time I ask this question, it leads to an in-depth discussion.

Other questions I’ve asked:

 

  • “What keeps you up at night?”
  • “If you were to leave this company, who would follow?”
  • “How do you handle an employee making a mistake?”
  • “If you were to give a Ted Talk, what topic would you talk about?”
  • “What are three highly valued skills at [company] that I should master to advance?”
  • “What are the informal expectations of the role?”
  • “What is one misconception people have about you [or the company]?”

 

Your questions reveal a great deal about your motivations, drive to make a meaningful impact on the business, and a chance to morph the questioning into a conversation. Cliché questions don’t lead to meaningful discussions, whereas unique, thought-provoking questions do and, in turn, make you memorable.

_____________________________________________________________________

 

Nick Kossovan, a well-seasoned veteran of the corporate landscape, offers “unsweetened” job search advice. You can send Nick your questions to artoffindingwork@gmail.com.

Continue Reading

Business

Canadian Natural Resources reports $2.27-billion third-quarter profit

Published

 on

 

CALGARY – Canadian Natural Resources Ltd. reported a third-quarter profit of $2.27 billion, down from $2.34 billion in the same quarter last year.

The company says the profit amounted to $1.06 per diluted share for the quarter that ended Sept. 30 compared with $1.06 per diluted share a year earlier.

Product sales totalled $10.40 billion, down from $11.76 billion in the same quarter last year.

Daily production for the quarter averaged 1,363,086 barrels of oil equivalent per day, down from 1,393,614 a year ago.

On an adjusted basis, Canadian Natural says it earned 97 cents per diluted share for the quarter, down from an adjusted profit of $1.30 per diluted share in the same quarter last year.

The average analyst estimate had been for a profit of 90 cents per share, according to LSEG Data & Analytics.

This report by The Canadian Press was first published Oct. 31, 2024.

Companies in this story: (TSX:CNQ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Cenovus Energy reports $820M Q3 profit, down from $1.86B a year ago

Published

 on

 

CALGARY – Cenovus Energy Inc. reported its third-quarter profit fell compared with a year as its revenue edged lower.

The company says it earned $820 million or 42 cents per diluted share for the quarter ended Sept. 30, down from $1.86 billion or 97 cents per diluted share a year earlier.

Revenue for the quarter totalled $14.25 billion, down from $14.58 billion in the same quarter last year.

Total upstream production in the quarter amounted to 771,300 barrels of oil equivalent per day, down from 797,000 a year earlier.

Total downstream throughput was 642,900 barrels per day compared with 664,300 in the same quarter last year.

On an adjusted basis, Cenovus says its funds flow amounted to $1.05 per diluted share in its latest quarter, down from adjusted funds flow of $1.81 per diluted share a year earlier.

This report by The Canadian Press was first published Oct. 31, 2024.

Companies in this story: (TSX:CVE)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending